Clinical-stage biopharmaceutical company DBV Technologies (Euronext Paris:DBV) (Nasdaq Capital Market:DBVT) on Friday announced a financing agreement of up to USD306.9m (EUR284.5m), including USD125.5m (EUR116.3m) upfront and up to USD181.4m (EUR168.2m) contingent on the full exercise of warrants.
These funds will support the preparation and submission of a Biologics License Application (BLA) for the Viaskin peanut patch, for the treatment of peanut allergy in children aged 4 to 7, and its potential US commercial launch. The financing will result in an immediate dilution of 22.4%, rising to 73.7% if all warrants are exercised.
The financing was led by MPM BioImpact, Adage Capital Management LP, Janus Henderson Investors, Vivo Capital and other healthcare-focused funds.
Hoth Therapeutics looks to expand HT-001 US patent coverage
Kazia Therapeutics sells Cantrixil intellectual property and trademarks to Vivesto for USD1m
Langhua Pharmaceutical passes US FDA's on-site inspection
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Dupixent receives approval in Japan as first biologic for COPD treatment
Celltrion adds STEQEYMA to Costco Member Prescription Program
Alys Pharmaceuticals doses first patient in Phase IIa trial of ALY-101
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories
Spyre Therapeutics starts dosing in Phase 1 clinical trial of SPY003
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's